The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TERN | +8.53% | N/A | N/A | -56% |
| S&P | +14.5% | +93.32% | +14.09% | +72% |
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
They could ride the wave of the hottest therapeutic area in the industry.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.11M | 55.0% |
| Market Cap | $325.77M | -26.0% |
| Market Cap / Employee | $5.52M | 0.0% |
| Employees | 59 | -10.6% |
| Net Income | -$24.09M | -6.0% |
| EBITDA | -$27.28M | -7.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $145.97M | 59.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.69M | 0.0% |
| Short Term Debt | $0.44M | 78.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -33.28% | 3.6% |
| Return On Invested Capital | -31.36% | 321.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$18.87M | -16.6% |
| Operating Free Cash Flow | -$18.87M | -16.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.68 | 1.29 | 0.70 | 1.00 | -46.30% |
| Price to Tangible Book Value | 2.68 | 1.29 | 0.70 | 1.00 | -46.30% |
| Enterprise Value to EBITDA | -11.22 | -5.78 | 2.96 | -1.00 | -91.03% |
| Return on Equity | -28.3% | -29.6% | -32.1% | -35.0% | -10.00% |
| Total Debt | $1.31M | $1.35M | $1.24M | $1.13M | 355.02% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
